Navigation Links
Study affirms value of epigenetic test for markers of prostate cancer
Date:5/28/2014

A multicenter team of researchers report that a commercial test designed to rule out the presence of genetic biomarkers of prostate cancer may be accurate enough to exclude the need for repeat prostate biopsies in many if not most men.

"Often, one biopsy is not enough to definitively rule out prostate cancer," says study researcher Jonathan Epstein, M.D., director of the Division of Surgical Pathology and a professor of pathology, urology and oncology at the Johns Hopkins University School of Medicine. "Our research finds that by looking for the presence or absence of cancer in a different way, we may be able to offer many men peace of mind without putting them through the pain, bleeding and risk of infection that can come with a repeat biopsy."

The new research, called the Detection of Cancer Using Methylated Events in Negative Tissue (DOCUMENT) study, suggests that an initial biopsy complemented with an epigenetic diagnostic test accurately rules out the existence of cancer up to 88 percent of the time. The test, developed by MDxHealth, which paid for the study, was described online in April in The Journal of Urology.

The test specifically captures the presence of chemical modifications to non-nuclear DNA sequences within cells that commonly appear when prostate cancer is present. These so-called epigenetic changes, which add a methyl group to the biochemical makeup of the DNA, alter the way genes function without changing their foundational DNA sequence. The researchers analyzed tissue from biopsies from 320 men with elevated prostate-specific antigen (PSA) levels whose results were negative for prostate cancer. The men were patients at The Johns Hopkins Hospital; the University of California, Los Angeles; the Cleveland Clinic; Eastern Virginia Medical School; and Lahey Hospital & Medical Center.

The epigenetic biomarkers the test detects reflect a process called DNA hypermethylation, in which a methyl group is chemically attached to DNA in this case, to genes called GSTP1, APC and RASSF1. These genes are known to play prominent tumor suppressive roles in key cancer-related pathways. When these genes are hypermethylated, they are commonly silenced, which can lead to a loss of this tumor-suppressing function and the emergence of cancer.

Specifically, the GSTP1 gene acts as a detoxifying agent, preventing genomic damage by carcinogens. Studies find that GSTP1 is methylated in up to 90 percent of prostate cancer cases, making it a strong indicator of the disease.

For the study, pathologists compared methylation levels between the subjects' initial tissue biopsies and later tissue samples taken from each man done within 24 months of the first biopsy. They found that average levels of APC and RASSF1 were about twice as high in the 92 subjects whose second biopsies yielded positive results, as compared to the 228 with two negative biopsies. For GSTP1, the levels were more than eight times higher in the cancerous biopsies.

"It turns out as many as 20 percent of men have prostate cancer, even if their first biopsy results are negative," says Epstein, the Rose-Lee and Keith Reinhard Professor of Urologic Pathology. Approximately 40 percent of men with a negative biopsy go on to receive a second biopsy. Many high-risk men fear sampling errors in their initial biopsy, which often leads to a high rate of follow-up procedures to merely confirm the absence of the disease.

Initial biopsies are typically performed when men receive abnormal results on PSA screenings or digital rectal exams. But an initial biopsy can sometimes miss cancer if none of the biopsy needles pass through the cancer, leading to the false-negative results.

"With prostate biopsies, there is often very little cancer, which makes it difficult to perform molecular prognostic and predictive tests," says Epstein. "The DOCUMENT study overcomes this problem, because it looks at benign tissue, not just the cancer. There is a lot of benign tissue, which is why we think it performs so well."

"Overall, if there is an absence of methylation in all three biomarkers, there is an 88 percent likelihood you don't have cancer," Epstein says. "The test isn't 100 percent of an assurance, but it is a major step forward."


'/>"/>
Contact: Stephanie Desmon
sdesmon1@jhmi.edu
410-955-8665
Johns Hopkins Medicine
Source:Eurekalert

Related medicine news :

1. Technology marketers should take consumer life-cycle into account: New Rotman study
2. Study identifies risk of chemotherapy related hospitalization for eary-stage breast cancer patients
3. Vanderbilt study finds women referred for bladder cancer less often than men
4. New University of Colorado study illuminates how cancer-killing gene may actually work
5. Just look, but dont touch: EMA terms of use for clinical study data are impracticable
6. Study: Some pancreatic cancer treatments may be going after the wrong targets
7. Study shows image fusion-guided biopsy improves accuracy of prostate cancer diagnosis
8. Gambling history is common among homeless people in Toronto, new study
9. More maternal mental health surveillance is needed, suggests new study
10. New study on mobile phones and childrens cognitive development
11. Scientists seek answers with space station thyroid cancer study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... , ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing ... acute or chronic problems, I focus on preventative care with all my patients to alleviate ... any questions, always feel free to contact my office and my trained staff will assist ...
(Date:4/25/2017)... ... 2017 , ... Amendia, Inc., designer, developer, and manufacturer of ... and platinum sponsorship of Global Spine Outreach (“GSO”), a charitable organization dedicated to ... spine deformity cases, particularly in children. , GSO’s focus is to provide hands-on ...
(Date:4/24/2017)... ... 2017 , ... Ridgecrest Herbals makes it a point to lead the Utah ... and support renewable energy. They believe this is a crucial part of their mission ... health issues, and maintain that destroying the environment in the pursuit of profit is ...
(Date:4/24/2017)... ... April 24, 2017 , ... The California Dental Association Foundation’s two-day volunteer ... to 1,961 people during the April 22-23 event at the San Mateo Event Center. ... experience barriers to care, CDA Cares educates the public and policymakers about the importance ...
(Date:4/24/2017)... ... April 24, 2017 , ... The world-class designers ... to bring their novel lifesaving device for the everyday use of parents worldwide. ... specially designed to read a child’s vital signs, and detect unusual symptoms or ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... -- New research provides evidence that an old drug may provide ... released today that will be presented at the American ... Boston , April 22 to 28, 2017. ... the oral drug levodopa has long been considered the gold ... disease progresses, the effects of the medication can partially wear ...
(Date:4/18/2017)... , April 18, 2017 Cogentix Medical, Inc. ... providing the Urology, Uro/Gyn and Gynecology markets with innovative ... first quarter ended March 31, 2017 after the market ... The Company will host a conference call and webcast ... Tuesday, May 2, 2017 at 4:30 p.m. Eastern Time ...
(Date:4/18/2017)... BLOOMINGTON, Minn. , April 18, 2017 /PRNewswire/ ... ("Imprimis"), an ophthalmology-focused pharmaceutical company, and Cameron Ehlen ... the signing of a three-year exclusive sales representation ... a dedicated sales team to introduce Imprimis, ophthalmic ... focused in 13 states in the U.S. Midwest. Precision ...
Breaking Medicine Technology: